Vafidemstat KDM1A Inhibition for Non-Aggressive BPD Symptoms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for borderline personality disorder (BPD) lack FDA-approved drugs and existing off-label medications have questionable efficacy and unwanted side effects, necessitating a need for novel therapies with a favorable side effect profile that can address core features of BPD.
Innovation Solution
The use of the KDM1A inhibitor vafidemstat or its pharmaceutically acceptable salts/solvates to treat non-aggressive symptoms of BPD, such as emotional instability and intense relationships, by administering it orally or through other routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If off-label medications (mood stabilizers and atypical antipsychotics) are used to treat BPD, then some symptoms may be addressed, but side effects such as sedation and weight gain occur and efficacy is questionable
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach by shifting from off-label use of psychiatric medications to a targeted biological mechanism approach. Vafidemstat selectively inhibits KDM1A enzyme, changing the treatment parameter from broad-spectrum psychiatric drugs to a specific epigenetic modifier that addresses underlying biological mechanisms of BPD without the side effects of traditional medications
Solution Approach 2:
The patent extracts and targets the specific KDM1A enzyme mechanism from the complex pathology of BPD. By identifying and inhibiting this specific biological target, the treatment isolates the therapeutic action to a precise molecular mechanism, avoiding the broad and non-specific effects of traditional psychiatric medications that cause unwanted side effects
2Adaptability or versatility
If no FDA-approved drugs are available for BPD, then treatment options are limited, but this creates an unmet medical need for novel therapies
Solution Approach 1:
The patent segments the unmet medical need into specific treatable targets by identifying KDM1A as a discrete biological mechanism underlying BPD symptoms. This segmentation allows for the development of targeted therapies that address specific pathological pathways rather than relying on broad, non-specific medications, thereby creating reliable treatment options where none previously existed
3Ease of operation
If current medications are used to treat core features of BPD, then some symptom management is achieved, but the side effect profile remains unfavorable compared to novel mechanisms
Solution Approach 1:
The patent introduces KDM1A inhibition as an intermediary mechanism between the drug and the complex symptoms of BPD. Vafidemstat acts as a mediator that targets the epigenetic regulation underlying multiple core features of BPD, providing therapeutic benefit across multiple symptoms while avoiding the direct side effects associated with traditional psychiatric medications
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are methods for treating borderline personality disorder using KDM1A inhibitors, particularly vafidemstat.